Tools, Diagnostics & CDMO

Kaipu Biotech announced that its wholly owned subsidiary, Chaozhou Kaipu Biochemical Co., Ltd., has obtained a medical device registration certificate issued by the National Medical Products Administration. The approved product is a vaginal microbial nucleic acid detection kit, using PCR-fluorescent probe method, classified as a Class III in vitro diagnostic reagent. The product is used for qualitative detection of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans nucleic acids in vaginal secretions.

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.

GE HealthCare announced a definitive agreement on October 5 to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. The deal builds on an exclusive licensing agreement struck in October 2023 covering development and commercialization of Fluorine-18 FAPI-74 outside the United States and global rights to Gallium-68 FAPI-46, and it would add U.S. rights to F-18 FAPI-74 while expanding GE HealthCare's domestic radiopharmaceutical manufacturing network. The company also recently received CE Mark approval for its Photonova Spectra photon-counting CT scanner, its third clearance across key geographies in five months. In the second quarter of fiscal 2026, adjusted EBIT margin fell 40 basis points year over year to 14.2%, though diluted EPS rose 16.5%, a figure that included a one-time $129 million tariff refund under the International Emergency Economic Powers Act. After $2.3 billion of strategic acquisitions in the first half, GE HealthCare reported $10.1 billion in total debt and $2.1 billion in cash and equivalents at quarter-end.

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

Danaher announced in early October 2026 that it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab's closed-loop system feeds every experimental result back into its AI models, a setup intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. The launch reinforces Danaher's Life Sciences automation and AI catalyst but does not materially change near-term sensitivities around bioprocessing demand or the risk that softer respiratory testing and China pricing could leave overall growth below what the market currently embeds. The announcement comes alongside the appointment of Julie Sawyer Montgomery as CEO from 1 October 2026, with execution on connected, automated workflows expected to depend heavily on leadership continuity and capital allocation discipline. Danaher's narrative projects $31.7 billion revenue and $6.1 billion earnings by 2029, requiring 8.1% yearly revenue growth and about a $2.1 billion earnings increase from $4.0 billion today, while three Simply Wall St Community fair value estimates cluster in a tight US$225.66 to US$239.86 range.

Tasly announced that its wholly-owned subsidiary Tianjin Tasly Pride Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Indocyanine Green for Injection approved and issued by the National Medical Products Administration. Indocyanine Green for Injection is clinically used to diagnose various liver diseases such as cirrhosis, hepatic fibrosis, chronic hepatitis, and occupational and drug-induced toxic liver disease, and to assess the degree of liver damage and its reserve function. The drug can also be used for choroidal angiography to determine the location of choroidal disorders.

Adaptive Biotechnologies' modeled fair value per share has been lifted from US$26.36 to US$28.31, reflecting analyst optimism around the clonoSEQ minimal residual disease franchise. Multiple firms have raised their fair value estimates in recent months, including TD Cowen, BTIG, Piper Sandler and Guggenheim, with Guggenheim most recently at US$32 and Goldman Sachs at US$35. Goldman Sachs sees Adaptive Biotechnologies as a leader in next generation sequencing minimal residual disease testing, with current penetration at about 13% of the potential patient population. On the bearish side, Craig Hallum has flagged possible confusion around the proposed 2027 Centers for Medicare and Medicaid Services clinical laboratory fee schedule, since some billing codes used by the company are among those facing proposed cuts of up to 15%, though the firm does not expect a significant direct financial impact. In the updated model, revenue growth has adjusted from 16.84% to 16.03%, net profit margin from 3.77% to 3.95%, future P/E from 328.9x to 344.6x, and the discount rate from 8.23% to 8.24%.

Guardant Health announced that Guardant360 CDx has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH, also known as camizestrant, in advanced ER-positive breast cancer. The test identifies patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from the next-generation oral selective estrogen receptor degrader and complete ER antagonist. Using a simple blood draw, clinicians can test for ESR1 mutations ahead of disease progression, and the European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan. The clearance marks the third companion diagnostic approval for ETCAMAH and the 31st companion diagnostic approval for Guardant Health. Chairman and co-CEO Helmy Eltoukhy said the company sees tremendous potential for this testing protocol to transform the treatment of other cancer types.

Thermo Fisher Scientific has helped launch the Digital CMC Consortium to advance digital Chemistry, Manufacturing, and Controls for biopharma. The initiative brings together biopharma companies, technology providers, and regulators to work on shared digital standards for CMC data, aiming to support faster therapy development, more efficient regulatory reviews, and digital lifecycle management across drug programs. Thermo Fisher Scientific operates across life sciences tools, diagnostics, and biopharma services, and its US$242.8b size gives it the breadth to help shape shared data standards that many pharma clients may end up using. The company already supports programs like Quantum BioPharma's Phase 2 Lucid MS trial and offers platforms such as OSD Express and Steriles Express that structure data and workflows across development and manufacturing. A practical signal to watch is how many drug programs and partners explicitly adopt Digital CMC based workflows or defined solutions such as OSD Express, Steriles Express or KinetiSol projects over the next CPHI cycle through late 2027.

RadNet posted the strongest quarter among the five testing and diagnostics services stocks tracked, reporting revenues of $622.7 million, up 25% year on year and 2.3% above analysts' expectations, with a beat on EPS estimates. Dr. Howard Berger, President and Chief Executive Officer of RadNet, said the Imaging Center and Digital Health reportable operating segments continued to demonstrate strong growth and achieve record quarterly results, with Total Company Revenue up 25.0% and Digital Health segment Revenue up 56.5% from last year's same quarter. As a group, the five testing and diagnostics services stocks tracked beat analysts' consensus estimates by 2.8%, and their share prices are up 7.2% on average since the latest earnings results. Quest Diagnostics reported revenues of $3.04 billion, up 10.2% year on year and 2.3% above expectations, while Guardant Health reported revenues of $335 million, up 44.3% year on year and 6.4% above expectations, scoring the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Labcorp delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers, with revenues of $3.73 billion, up 5.8% year on year and in line with analysts' expectations, while NeoGenomics reported revenues of $201.7 million, up 11.2% year on year and 2.2% above expectations.

Haemonetics Corporation shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc. CSL announced on October 8, 2026, that it expects to complete the rollout of Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of calendar year 2027, according to an 8-K filing, and told Haemonetics it currently anticipates the transition will occur at all of its U.S. plasma collection centers. The companies initially entered into the non-exclusive supply agreement on August 18, 2026, under which CSL may utilize Haemonetics' devices and purchase related disposables in the United States. Haemonetics said the scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement and that implementation details are still to be determined, and it is not updating its previously issued fiscal 2027 guidance at this time. The company expects to provide an update regarding the anticipated impact of the supply agreement on its fiscal 2027 financial results during its second fiscal quarter earnings call in November 2026.

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score technology, known as PrGIS, with AstraZeneca. PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients, and Myriad's proprietary MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad's PrGIS technology, drawing on a cloud-based platform with more than 1,000 connected institutions in over 75 countries. Myriad also plans to present PrGIS research co-authored with AstraZeneca at the European Society for Medical Oncology Congress 2026, with full data available after the ESMO embargo period.

Avricore Health Inc. announced that its wholly owned subsidiary HealthTab Ltd. has completed an integration with HeartEye, a UK provider of AI-based retinal cardiovascular risk assessment, creating a new referral pathway into community pharmacy. Under the pathway, people found to be at elevated cardiovascular risk by a HeartEye retinal scan at their optician can be referred to a nearby HealthTab-enabled pharmacy for further assessment and care. HeartEye's Dr.Noon CVD test, developed by Mediwhale, uses AI to estimate cardiovascular risk from a retinal scan taken during a routine optician visit; when a patient is flagged at elevated risk, their Dr.Noon report QR code can be scanned into HealthTab at a nearby pharmacy, where a pharmacist carries out a point-of-care cholesterol test that feeds an automatic QRISK3 calculation, with all results displayed together on the patient's HealthTab dashboard. With newly qualified pharmacists in England registering as independent prescribers from September 2026, the pathway has the potential to take patients from identification and assessment through to treatment, where appropriate, within the community, supporting all three of the NHS 10 Year Health Plan's major shifts. HealthTab and Abbott will showcase their turnkey pharmacy-based point-of-care testing solution, including the new HeartEye integration, at The Pharmacy Show 2026 on October 11-12 at the NEC in Birmingham.

Oriental Ocean announced that its subsidiary, Mass Spectrometry Biotechnology Co., Ltd., has recently obtained a medical device registration certificate from the Shandong Provincial Medical Products Administration for its independently developed water-soluble vitamin assay kit using liquid chromatography-tandem mass spectrometry. The product is intended for in vitro quantitative determination of vitamins B1, B2, B3, B5, B6, B7, and B9 in human serum, further enriching the subsidiary's product line in the clinical testing field. The company cautioned that the product has not yet entered production after obtaining the certificate, and actual sales will be affected by multiple factors including market expansion efforts and demand, so the impact on performance remains uncertain.

Lifotronic Technology announced on October 8 that it has recently received notification from the U.S. Food and Drug Administration that its H100Plus hemoglobin testing system has obtained FDA 510(k) clearance. The product is intended for in vitro quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which can assist in the diagnosis of diabetes. The company stated that obtaining FDA clearance demonstrates that the product meets the relevant requirements of the U.S. Food and Drug Administration and is qualified to enter the U.S. market. In the first half of 2026, Lifotronic Technology achieved revenue of 604 million yuan and net profit attributable to the parent company of 79.27 million yuan.

Bangkok Genomics Innovation Public Company Limited, or BKGI, reported first-half 2026 results with net profit of 62.05 million baht, up 49.65 million baht, or 400%, from net profit of 12.40 million baht in the same period a year earlier. Total revenue came to 309.39 million baht, up 157.02 million baht, or 103%, from total revenue of 152.37 million baht in the same period last year. Dr. Saowalak Dansakul, Chief Executive Officer of BKGI, said the company is transitioning from a provider of NIFTY testing services to a full-service health and genomics innovation provider through three business models: instrument placement with reagent purchases, instrument purchases with reagent purchases, and instrument leasing with reagent purchases. It is also expanding its Precision Oncology portfolio with the OncoPRESS service and BRCA 1/2 testing, which are already partially reimbursed by the National Health Security Office. On revenue structure, the share from instrument and reagent sales rose to 55%, above the 45% from services, with reagent sales, which are recurring revenue, accounting for 36% of total revenue, or about 110 million baht, and the company expects to begin recognising significant revenue from reagent use starting in the third quarter of 2026. The ATMP group has begun contributing about 40.4 million baht in revenue and will become a driver of continuous reagent sales from 2027 onward. The company is also studying the feasibility of producing reagents in Thailand to manage supply chain and logistics risks, and expects second-half 2026 operating results to grow from the first half, supported by Oncology, Wellness & Longevity, NGS and ATMP, as well as the government-backed Phase 2 of the Genomics Thailand project.

Danaher Corporation announced plans to launch its first AI-powered autonomous lab for antibody research, sending its shares up 2% in premarket trading Wednesday. The facility, expected to operate at scale in early 2027, will combine artificial intelligence, robotics and technologies from several Danaher operating companies to help researchers develop custom antibodies and other molecular tools, and is designed to deliver up to 8x faster discovery of affinity reagents and unlock up to a tenfold increase in annual reagent generation. Based at Abcam, a Danaher company, the lab uses AI to create new affinity reagents, including antibodies, then builds and tests each one, feeding results back into the model to improve subsequent designs, bringing together technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices in one connected workflow. Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher, said the autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver, helping turn promising ideas into validated systems faster. The lab represents the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research. Ahead of Wednesday's announcement, Barclays analyst Luke Sergott raised the price target on Danaher to $255.00 from $230.00 while maintaining an Overweight rating.

Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique to support Ebola testing capacity in the Democratic Republic of Congo, where an outbreak caused by Bundibugyo virus has pushed demand for testing beyond current laboratory capacity. Roche will preconfigure the Light cycler and Magna Pure instruments and train local laboratory technicians before deploying the equipment to Bunia for validation testing. The Institut National de Santé Publique will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed. The delivery follows Roche's June announcement that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, a case fatality rate of 48.4% across 60 health zones in six provinces, and the WHO has assessed the risk in the DRC as very high and confirmed the outbreak remains a public health emergency of international concern.

Alvotech announced on Tuesday that it has agreed to a long-term deal with LOTTE Biologics to manufacture multiple biosimilar drugs at LOTTE's Syracuse, New York facility. The agreement adds 40K liters of manufacturing capacity and expands Alvotech's U.S. production footprint. The added capacity will support the company's growing biosimilar pipeline and global supply needs, with potential for the partnership to expand. Commercial production will begin after required technology transfer, facility qualification, and regulatory approvals.

QIAGEN N.V. announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis, and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons, and Dr. Simona Chera, Professor at the University of Bergen, said the tool identified the problem, cautioned against overinterpreting the results and suggested a better experimental design.

NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.

Oku Digital Health, Inc. announced its global launch from Topcon Healthcare, Inc., unveiling an AI-powered digital health company that turns routine eye exams into a front door for early disease detection and accelerated clinical development. The company operationalizes its Healthcare from the Eye approach across a connected network of more than 10,000 care locations, built on Topcon's global installed base of 50,000+ diagnostic devices, and says it has screened over 2.2 million patients outside of traditional eye care. Oku combines AI-supported diagnostics, EHR integration, and referral workflows to connect healthcare providers in primary care, optometry, ophthalmology, and specialties with pharmaceutical partners seeking patient data and real-world evidence for drug development and precision medicine. Ali Tafreshi, who remains Chief Strategy Officer for Topcon Corp.'s Eyecare Business Division and Chief Executive Officer of Topcon Healthcare Inc., leads Oku as Chief Executive Officer, joined by Chief Operating Officer Trent Norris, Chief Data AI Officer Matthew Lungren, Chief Medical Officer Daniela Ferrara, and Chief Strategy and Business Development Officer Jacques Gilbert. The company is built on Microsoft Azure cloud infrastructure and optimized for AI workloads with NVIDIA CUDA libraries, and will make its debut at the American Academy of Ophthalmology Annual Meeting in New Orleans from October 9 to 12, 2026, within the Topcon Healthcare booth at AAO 1737.

Bruker Corporation announced a seminal bioRxiv preprint describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution, conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. By combining intact protein fractionation with diaPASEF mass spectrometry on Bruker timsTOF mass spectrometry systems, the researchers detected 5,077 plasma protein groups across 179,049 distinct proteoforms, with a high-confidence map comprising 44,083 proteoforms and a median of eleven proteoforms per protein. The study indicates that canonical proteins account only for a fraction of protein diversity in the blood stream and may constitute less than half of total protein content, and the workflow did not use nanoparticle-based enrichment. Dr. Markus Ralser, Einstein Professor of Biochemistry and Head of the Institute of Biochemistry at Charité – Universitätsmedizin Berlin, said the first draft of the plasma proteoform atlas shows that proteoforms are not rare exceptions but a defining feature of plasma biology. The preprint, titled "A draft atlas of the human plasma proteome at isoform resolution," was posted on September 28, 2026, and the draft isoform atlas is intended as a starting point for future proteoform in-depth studies across individuals, physiological states and diseases.

Telix Pharmaceuticals announced that the first patients in the United States have been dosed with Pixclara, its FDA-approved amino acid PET imaging drug for glioma, marking the start of U.S. commercial availability. The doses were administered at the Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center in Cleveland, with Telix's U.S. manufacturing and pharmacy distribution partner PharmaLogic Holdings Corp. supplying finished unit doses to the U.S. market. Pixclara, also known as floretyrosine F 18 or 18F-FET, is the only FDA-approved radiopharmaceutical imaging drug for glioma and is indicated to help differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients one month of age and older. Gliomas account for approximately 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors, with roughly 24,000 new glioma cases diagnosed in the U.S. each year. Telix said Pixclara is also the subject of a Phase 3 registrational study for potential indication expansion into the diagnosis of brain metastases.

President Donald Trump said Monday that Becton Dickinson has agreed to invest $3B to bring manufacturing of essential medical products to the United States. In a post on Truth Social, Trump said the medical technology company will invest more than $1B in Nebraska to ramp up production of numerous products, including needles made with American steel. Trump attributed the announcement to his "strong Medical Device TARIFFS, which will be in place by the end of the year." BDX shares closed 2.2% higher on Monday.

Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI tool for early mitral regurgitation detection. The clearance landed on top of a strong run in the shares, with a 1-day share price return of 9.03% lifting the latest quote to US$83.55 and building on a 30-day share price return of 29.29%, though the 1-year total shareholder return remains down 10.17%. The stock now trades above the average analyst target and above some intrinsic value estimates, with the most followed narrative anchoring fair value nearer $75.68, framing the latest close as roughly 10% overvalued. The company reported Q2 revenue growth of 22% year over year, with oncology testing volumes up 31% and Data Licensing and Modeling revenue up 36%, and it raised 2026 revenue guidance to around $1.6 billion while expecting approximately $65 million of Adjusted EBITDA. Risks to the story include a drag on profitability from the integration of Personalis and cooling expectations around AI products.

Safe Fertility Group Public Company Limited, or SAFE, disclosed that it is studying ways to expand cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, in order to add revenue channels and extend its business, with clarity expected within next year. As for its operating performance trend in 2027, the company targets revenue growth of about 10-15% from 2026, when revenue is expected to be close to the previous year's 900 million baht, driven by expanding its business scope into genetic testing laboratories under Next Generation Genomic Company Limited, which provides testing services in reproductive medicine and maternal and child medicine to leading public and private healthcare facilities, as well as obstetrics and gynecology clinics both domestically and overseas. At present, SAFE's customer base is split roughly 50% Thai customers and 50% foreign customers, but in terms of revenue, about 60% comes from foreign customers and about 40% from Thai customers, because service rates for foreign customers are about 15-20% higher. It is also looking for opportunities to expand into the Bangladesh and Indonesia markets in the future. In addition, SAFE aims to expand its family care base from 40,000 families to 50,000 families within the next 3-5 years, while driving average revenue growth of 10-15% per year through its Preserve and Prevent market growth strategies and by expanding its foreign patient base, which currently accounts for as much as 50% of all patients. Over the longer term, in the next 5-10 years, SAFE's goal is to push Thailand to become a Regional Fertility Hub that families across the region trust.

Illumina shares jumped 7.7% in the afternoon session after Wall Street analysts raised their price targets on the genomics company, citing expected improvement in clinical sales and new catalysts. Analysts also pointed to growing investor interest in gene-sequencing technology as foundational infrastructure for artificial intelligence applications, according to TipRanks. The stock closed the day at $293.84, up 7.6% from the previous close, and has now gained 119% since the beginning of the year, setting a new 52-week high. The move was notable but not extreme for Illumina, which has seen 17 swings greater than 5% over the past year. The largest of those came 11 months ago, when the stock gained 22.4% after the company reported third-quarter 2025 results that beat profit expectations and raised its full-year guidance.